Lineage Cell Therapeutics shared details from its Q2 2026 earnings call, showing $50.8 million in cash.

Oct 12, 2026, 7:52 AM ETResultsRead the original at Benzinga

Neutral

Lineage reported cash expected to fund operations into Q3 2028 and progress in new programs. Revenue fell, and reported income came from a non-cash gain, so the call gives mixed signals without clearly changing the company's prospects.

LCTX · Lineage Cell Therapeutics

AI read · Neutral

The AI's read

The cash runway gives Lineage time to develop its newer cell programs. Roche and Genentech may provide up to $615 million, but Lineage is eligible for that amount, not guaranteed to receive it. Revenue fell, and reported net income came from a non-cash gain. Those results balance the cash and pipeline progress, so the call does not point clearly in one direction.

Get alerts for LCTX

Follow Lineage Cell Therapeutics (LCTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LCTX

Free on the App Store and Google Play, or on the web.